Erratum: Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol (Journal of Lipid Research (2015) 56 (463-469) DOI: 10.1194/jlr.M055780);Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol

Journal of Lipid Research

Volumn 56, Issue 2, 2015, Pages 463-469

  Ghosh, Moumita ^a,b,c,d   Gälman, Cecilia ^a,b,d   Rudling, Mats ^a,b,c,d   Angelin, Bo ^a,b,c,d  

^a Metabolism Unit Department of Endocrinology Metabolism and Diabetes   (Sweden)

^b Center for Infectious Medicine   (Sweden)

^c ASTRAZENECA   (United Kingdom)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Low density lipoprotein cholesterol; Menopause; Menstruation cycle; Proprotein convertase subtilisin kexin type 9

Indexed keywords

ESTRADIOL; ESTROGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN PCSK9; SERINE PROTEINASE; UNCLASSIFIED DRUG; PCSK9 PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; AGED; AGING; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; ESTROGEN BLOOD LEVEL; FEMALE; FOLLICULAR PHASE; HUMAN; HUMAN EXPERIMENT; LIFE CYCLE STAGE; LUTEAL PHASE; MALE; MENSTRUAL CYCLE; NORMAL HUMAN; OVULATION; POSTMENOPAUSE; PREMENOPAUSE; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; VERY ELDERLY; VOLUNTEER; BLOOD; METABOLISM; MIDDLE AGED; PHYSIOLOGY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CHOLESTEROL, LDL; ESTROGENS; FEMALE; HUMANS; MALE; MENSTRUAL CYCLE; MIDDLE AGED; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; SEX FACTORS; YOUNG ADULT;

EID: 84921935725     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M055780ERR     Document Type: Erratum

References (33)

1. Blackett, P. R., and D. K. Sanghera . 2013 . Genetic determinants of cardiometabolic risk: a proposed model for phenotype association and interaction. J. Clin. Lipidol. 7 : 65-81 .
2. Rudling, M., B. Angelin, L. Stahle, E. Reihner, S. Sahlin, H. Olivecrona, I. Bjorkhem, and C. Einarsson . 2002 . Regulation of hepatic low-density lipoprotein receptor, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and cholesterol 7alpha-hydroxylase mRNAs in human liver. J. Clin. Endocrinol. Metab. 87 : 4307-4313 .
3. Horton, J. D. 2002 . Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis. Biochem. Soc. Trans. 30 : 1091-1095 .
4. Seidah, N. G., and A. Prat . 2012 . The biology and therapeutic targeting of the proprotein convertases. Nat. Rev. Drug Discov. 11 : 367-383 .
5. Kosenko, T., M. Golder, G. Leblond, W. Weng, and T. A. Lagace . 2013 . Low density lipoprotein binds to proprotein convertase subtilisin/ kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation. J. Biol. Chem. 288 : 8279-8288 .
6. Lopez, D. 2008 . PCSK9: an enigmatic protease. Biochim. Biophys. Acta . 1781 : 184-191 .
7. Cui, Q., X. Ju, T. Yang, M. Zhang, W. Tang, Q. Chen, Y. Hu, J. V. Haas, J. S. Troutt, R. T. Pickard, et al . 2010 . Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. Atherosclerosis . 213 : 632-636 .
8. Lakoski, S. G., T. A. Lagace, J. C. Cohen, J. D. Horton, and H. H. Hobbs . 2009 . Genetic and metabolic determinants of plasma PCSK9 levels. J. Clin. Endocrinol. Metab. 94 : 2537-2543 .
9. Cohen, J. C., E. Boerwinkle, T. H. Mosley, Jr ., and H. H. Hobbs . 2006 . Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354 : 1264-1272 .
10. Abifadel, M., M. Varret, J. P. Rabes, D. Allard, K. Ouguerram, M. Devillers, C. Cruaud, S. Benjannet, L. Wickham, D. Erlich, et al . 2003 . Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34 : 154-156 .
11. Chernogubova, E., R. Strawbridge, H. Mahdessian, A. Malarstig, S. Krapivner, B. Gigante, M. L. Hellenius, U. de Faire, A. Franco-Cereceda, A. C. Syvanen, et al . 2012 . Common and low-frequency genetic variants in the PCSK9 locus infl uence circulating PCSK9 levels. Arterioscler. Thromb. Vasc. Biol. 32 : 1526-1534 .
12. Benjannet, S., J. Hamelin, M. Chretien, and N. G. Seidah . 2012 . Loss- and gain-of-function PCSK9 variants: cleavage specifi city, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation. J. Biol. Chem. 287 : 33745-33755 .
13. Persson, L., C. Galman, B. Angelin, and M. Rudling . 2009 . Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors. Endocrinology . 150 : 1140-1146 .
14. Persson, L., P. Henriksson, E. Westerlund, O. Hovatta, B. Angelin, and M. Rudling . 2012 . Endogenous estrogens lower plasma PCSK9 and LDL cholesterol but not Lp(a) or bile acid synthesis in women. Arterioscler. Thromb. Vasc. Biol. 32 : 810-814 .
15. Matasconi, M., P. Parini, B. Angelin, and M. Rudling . 2005 . Pituitary control of cholesterol metabolism in normal and LDL receptor knock-out mice: effects of hypophysectomy and growth hormone treatment. Biochim. Biophys. Acta . 1736 : 221-227 .
16. Costet, P., B. Cariou, G. Lambert, F. Lalanne, B. Lardeux, A. L. Jarnoux, A. Grefhorst, B. Staels, and M. Krempf . 2006 . Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J. Biol. Chem. 281 : 6211-6218 .
17. Bonde, Y., O. Breuer, D. Lutjohann, S. Sjoberg, B. Angelin, and M. Rudling . 2014 . Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans. J. Lipid Res. 55 : 2408-2415 .
18. Grundy, S. M., G. L. Vega, and D. W. Bilheimer . 1985 . Kinetic mechanisms determining variability in low density lipoprotein levels and rise with age. Arteriosclerosis . 5 : 623-630 .
19. Ericsson, S., M. Eriksson, S. Vitols, K. Einarsson, L. Berglund, and B. Angelin . 1991 . Infl uence of age on the metabolism of plasma low density lipoproteins in healthy males. J. Clin. Invest. 87 : 591-596 .
20. Roeters van Lennep, J. E., H. T. Westerveld, D. W. Erkelens, and E. E. van der Wall . 2002 . Risk factors for coronary heart disease: implications of gender. Cardiovasc. Res. 53 : 538-549 .
21. Gälman, C., B. Angelin, and M. Rudling . 2011 . Pronounced variation in bile acid synthesis in humans is related to gender, hypertriglyceridaemia and circulating levels of fi broblast growth factor 19. J. Intern. Med. 270 : 580-588 .
22. Friedewald, W. T., R. I. Levy, and D. S. Fredrickson . 1972 . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18 : 499-502 .
23. Montgomery, M. M., and S. J. Shultz . 2010 . Isometric knee-extension and knee-fl exion torque production during early follicular and postovulatory phases in recreationally active women. J. Athl. Train. 45 : 586-593 .
24. Mumford, S. L., E. F. Schisterman, A. M. Siega-Riz, R. W. Browne, A. J. Gaskins, M. Trevisan, A. Z. Steiner, J. L. Daniels, C. Zhang, N. J. Perkins, et al . 2010 . A longitudinal study of serum lipoproteins in relation to endogenous reproductive hormones during the menstrual cycle: fi ndings from the BioCycle study. J. Clin. Endocrinol. Metab. 95 : E80-E85 .
25. Silfverstolpe, G., A. Gustafson, G. Samsioe, and A. Svanborg . 1980 . Lipid metabolic studies in oophorectomized women: effects induced by two different estrogens on serum lipids and lipoproteins. Gynecol. Obstet. Invest. 11 : 161-169 .
26. Angelin, B., and M. Rudling . 2010 . Lipid lowering with thyroid hormone and thyromimetics. Curr. Opin. Lipidol. 21 : 499-506 .
27. Rudling, M., G. Norstedt, H. Olivecrona, E. Reihner, J. A. Gustafsson, and B. Angelin . 1992 . Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. Proc. Natl. Acad. Sci. USA . 89 : 6983-6987 .
28. Cariou, B., C. Langhi, M. Le Bras, M. Bortolotti, K. A. Le, F. Theytaz, C. Le May, B. Guyomarc'h-Delasalle, Y. Zair, R. Kreis, et al . 2013 . Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets. Nutr. Metab. (Lond) . 10 : 4 .
29. Brouwers, M. C., R. J. Konrad, T. M. van Himbergen, A. Isaacs, S. Otokozawa, J. S. Troutt, E. J. Schaefer, M. M. van Greevenbroek, A. F. Stalenhoef, and J. de Graaf . 2013 . Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia. Nutr. Metab. Cardiovasc. Dis. . 23 : 1115-1121 .
30. Persson, L., G. Cao, L. Stahle, B. G. Sjoberg, J. S. Troutt, R. J. Konrad, C. Galman, H. Wallen, M. Eriksson, I. Hafstrom, et al . 2010 . Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. Arterioscler. Thromb. Vasc. Biol. 30 : 2666-2672 .
31. Browning, J. D., and J. D. Horton . 2010 . Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans. J. Lipid Res. 51 : 3359-3363 .
32. Nilsson, L. M., A. Abrahamsson, S. Sahlin, U. Gustafsson, B. Angelin, P. Parini, and C. Einarsson . 2007 . Bile acids and lipoprotein metabolism: effects of cholestyramine and chenodeoxycholic acid on human hepatic mRNA expression. Biochem. Biophys. Res. Commun. 357 : 707-711 .
33. Parker, R. A., R. Garcia, C. S. Ryan, X. Liu, P. Shipkova, V. Livanov, P. Patel, and S. P. Ho . 2013 . Bile acid and sterol metabolism with combined HMG-CoA reductase and PCSK9 suppression. J. Lipid Res. 54 : 2400-2409 .